The Analyst Landscape: 13 Takes On Edwards Lifesciences
Portfolio Pulse from Benzinga Insights
13 analysts have provided varied opinions on Edwards Lifesciences (NYSE:EW) over the past quarter, with ratings ranging from bullish to indifferent. The average 12-month price target has increased by 6.04% to $96.23. Key financial metrics show positive revenue growth, strong net margins, and effective debt management.
July 02, 2024 | 6:02 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Edwards Lifesciences (NYSE:EW) has received mixed analyst ratings over the past quarter, with an average 12-month price target of $96.23, up 6.04%. The company shows strong financial performance with 9.5% revenue growth, a 22.02% net margin, and effective debt management.
The mixed analyst ratings and increased average price target suggest a positive outlook for Edwards Lifesciences. The company's strong financial metrics, including revenue growth and net margins, further support a likely short-term price increase.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100